Rapport Therapeutics, Inc. (RAPP) 8-K Current Report: March 10, 2026
Filed: March 10, 2026
Health Care
Pharmaceutical PreparationsRapport Therapeutics, Inc. (RAPP) 8-K current report filed with SEC EDGAR on March 10, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 2.02: Results of Operations and Financial Condition
Rapport Therapeutics, Inc. 8-K Mar 10, 2026 Event Analysis
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results announced March 10, 2026
- • Full details — revenue, expenses, cash position — contained in Exhibit 99.1 press release
- • RAPP is a clinical-stage biotech; key investor focus should be on cash runway and pipeline milestones, not revenue
Get deeper insights on Rapport Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.